1887

Abstract

Hepatitis B virus (HBV) infections can be prevented or controlled by the host humoral immune response (anti-HBs) directed against the major surface antigen (HBsAg), elicited either naturally or by vaccination. A chronic HBV carrier was found to have high levels of both virus and anti-HBs. Full-length HBV genomes were amplified from the patient's serum, sequenced and cloned. The genome was ‘wild-type’ HBV of genotype C and serotype . The sequence has remained stable, with no signs of emergence of an immune-escape mutant population. To study what was recognized by the patient's serum, viral particles were S-labelled and then immunoprecipitated by using the patient's serum or control sera. The patient's serum immunoprecipitated the HBsAg encoded by his HBV genome poorly, but efficiently recognized HBsAg of serotype . When his HBV genome was modified by a point mutation to express HBsAg of serotype , the patient's serum could recognize the antigen, as well as the control anti-HBs-positive serum. The patient appeared to have made a quasi-monoclonal humoral response to the epitope. By switching to the epitope, which requires only a point mutation, the virus could replicate, despite the high levels of anti-HBs. This study underlines the subtleties of virus–host interactions. Implications for HBV vaccination are discussed.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80810-0
2005-06-01
2020-08-05
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/6/vir861687.html?itemId=/content/journal/jgv/10.1099/vir.0.80810-0&mimeType=html&fmt=ahah

References

  1. Alestig E., Hannoun C., Horal P., Lindh M. 2001; Phylogenetic origin of hepatitis B virus strains with precore C-1858 variant. J Clin Microbiol 39:3200–3203 [CrossRef]
    [Google Scholar]
  2. Bahn A., Gerner P., Martiné U., Bortolotti F., Wirth S. 1997; Detection of different viral strains of hepatitis B virus in chronically infected children after seroconversion from HBsAg to anti-HBs indicating viral persistence. J Hepatol 27:973–978 [CrossRef]
    [Google Scholar]
  3. Basuni A. A., Carman W. F. 2004; HBV vaccine-escape variants. Methods Mol Med 95:115–124
    [Google Scholar]
  4. Chen W. N., Oon C. J. 1999; Human hepatitis B virus mutants: significance of molecular changes. FEBS Lett 453:237–242 [CrossRef]
    [Google Scholar]
  5. Chen Y.-C. J., Delbrook K., Dealwis C., Mimms L., Mushahwar I. K., Mandecki W. 1996; Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library. Proc Natl Acad Sci U S A 93:1997–2001 [CrossRef]
    [Google Scholar]
  6. Coleman P. F., Chen Y.-C. J., Mushahwar I. K. 1999; Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol 59:19–24 [CrossRef]
    [Google Scholar]
  7. Günther S., Li B.-C., Miska S., Krüger D. H., Meisel H., Will H. 1995; A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 69:5437–5444
    [Google Scholar]
  8. Hannoun C., Horal P., Lindh M. 2000; Long-term mutation rates in the hepatitis B virus genome. J Gen Virol 81:75–83
    [Google Scholar]
  9. Hino K., Katoh Y., Vardas E., Sim J., Okita K., Carman W. F. 2001; The effect of introduction of universal childhood hepatitis B immunization in South Africa on the prevalence of serologically negative hepatitis B virus infection and the selection of immune escape variants. Vaccine 19:3912–3918 [CrossRef]
    [Google Scholar]
  10. Ireland J. H., O'Donnell B., Basuni A. A., Kean J. D., Wallace L. A., Lau G. K., Carman W. F. 2000; Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays. Hepatology 31:1176–1182 [CrossRef]
    [Google Scholar]
  11. Jack A. D., Hall A. J., Maine N., Mendy M., Whittle H. C. 1999; What level of hepatitis B antibody is protective?. J Infect Dis 179:489–492 [CrossRef]
    [Google Scholar]
  12. Jeantet D., Chemin I., Mandrand B., Zoulim F., Trepo C., Kay A. 2002; Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen-negative patient. Hepatology 35:1215–1224 [CrossRef]
    [Google Scholar]
  13. Kao J.-H., Chen D.-S. 2002; Global control of hepatitis B virus infection. Lancet Infect Dis 2:395–403 [CrossRef]
    [Google Scholar]
  14. Kidd-Ljunggren K., Miyakawa Y., Kidd A. H. 2002; Genetic variability in hepatitis B viruses. J Gen Virol 83:1267–1280
    [Google Scholar]
  15. Kohno H., Inoue T., Tsuda F., Okamoto H., Akahane Y. 1996; Mutations in the envelope gene of hepatitis B virus variants co-occurring with antibody to surface antigen in sera from patients with chronic hepatitis B. J Gen Virol 77:1825–1831 [CrossRef]
    [Google Scholar]
  16. Koziol D. E., Alter H. J., Kirchner J. P., Holland P. V. 1976; The development of HBsAg-positive hepatitis despite the previous existence of antibody to HBsAg. J Immunol 117:2260–2262
    [Google Scholar]
  17. Le Bouvier G. L., Capper R. A., Williams A. E., Pelletier M., Katz A. J. 1976; Concurrently circulating hepatitis B surface antigen and heterotypic anti-HBs antibody. J Immunol 117:2262–2264
    [Google Scholar]
  18. Mizokami M., Orito E., Ohba K., Ikeo K., Lau J. Y. N., Gojobori T. 1997; Constrained evolution with respect to gene overlap of hepatitis B virus. J Mol Evol 44 (Suppl. 1):S83–S90 [CrossRef]
    [Google Scholar]
  19. Norder H., Couroucé A.-M., Magnius L. O. 1992; Molecular basis of hepatitis B virus serotype variations within the four major subtypes. J Gen Virol 73:3141–3145 [CrossRef]
    [Google Scholar]
  20. Norder H., Couroucé A.-M., Coursaget P., Echevarria J. M., Lee S.-D., Mushahwar I. K., Robertson B. H., Locarnini S., Magnius L. O. 2004; Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 47:289–309 [CrossRef]
    [Google Scholar]
  21. Ogura Y., Kurosaki M., Asahina Y., Enomoto N., Marumo F., Sato C. 1999; Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus. J Infect Dis 180:1444–1451 [CrossRef]
    [Google Scholar]
  22. Okamoto H., Imai M., Tsuda F., Tanaka T., Miyakawa Y., Mayumi M. 1987; Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr. J Virol 61:3030–3034
    [Google Scholar]
  23. Oon C.-J., Chen W. N. 1998; Current aspects of hepatitis B surface antigen mutants in Singapore. J Viral Hepat 5 (Suppl. 2):17–23 [CrossRef]
    [Google Scholar]
  24. Oon C.-J., Chen W. N., Koh S., Lim G. K. 1999; Identification of hepatitis B surface antigen variants with alterations outside the “a” determinant in immunized Singapore infants. J Infect Dis 179:259–263 [CrossRef]
    [Google Scholar]
  25. Persson B., Argos P. 1994; Prediction of transmembrane segments in proteins utilising multiple sequence alignments. J Mol Biol 237:182–192 [CrossRef]
    [Google Scholar]
  26. Poovorawan Y., Theamboonlers A., Vimolket T. 7 other authors 2000; Impact of hepatitis B immunisation as part of the EPI. Vaccine 19:943–949 [CrossRef]
    [Google Scholar]
  27. Robinson W. S. 1999; Hepadnaviruses ( Hepadnaviridae ): hepatitis B virus: general features. In Encyclopedia of Virology , 2nd edn. pp  640–645 Edited by Granoff A., Webster R. G. San Diego: Academic Press;
    [Google Scholar]
  28. Sasaki T., Ohkubo Y., Yamashita Y., Imai M., Miyakawa Y. 1976; Co-occurrence of hepatitis B surface antigen of a particular subtype and antibody to a heterologous subtypic specificity in the same serum. J Immunol 117:2258–2259
    [Google Scholar]
  29. Torresi J. 2002; The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 25:97–106
    [Google Scholar]
  30. Viviani S., Jack A., Hall A. J., Maine N., Mendy M., Montesano R., Whittle H. C. 1999; Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 17:2946–2950 [CrossRef]
    [Google Scholar]
  31. Zaaijer H. L., Lelie P. N., Vandenbroucke-Grauls C. M. J. E., Koot M. 2002; Concurrence of hepatitis B surface antibodies and surface antigen: implications for postvaccination control of health care workers. J Viral Hepat 9:146–148 [CrossRef]
    [Google Scholar]
  32. Zöllner B., Petersen J., Schröter M., Laufs R., Schoder V., Feucht H.-H. 2001; 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 357:934–935 [CrossRef]
    [Google Scholar]
  33. Zuckerman A. J., Zuckerman J. N. 1999; Molecular epidemiology of hepatitis B virus mutants. J Med Virol 58:193–195 [CrossRef]
    [Google Scholar]
  34. Zuckerman J. N., Zuckerman A. J. 2003; Mutations of the surface protein of hepatitis B virus. Antiviral Res 60:75–78 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80810-0
Loading
/content/journal/jgv/10.1099/vir.0.80810-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error